Neuromod Devices has announced the appointment of Diarmuid Flavin as chief operating officer (COO). Flavin brings more than 25 years of global leadership experience in a range of medical device, technology and pharmaceutical companies to Neuromod, where he will assume responsibility for the company’s strategic operational execution, regulatory affairs, engineering and technology, manufacturing operations and supply chain teams.
Most recently, Flavin was director of Global Quality Compliance for TE Connectivity Medical & Healthcare. He also spent five years at Biosensia as CEO and COO, aiding in commercialising its Rapiplex in vitro diagnostics point of care platform technology. Flavin has also held senior leadership and technical roles at Abbott Vascular and Mylan.
Ross O’Neill, founder and CEO at Neuromod, said: “I have known Diarmuid for many years since his days at Biosensia, and I have seen the impact he has had in both global medtech companies and start-ups, so I am delighted to welcome him to Neuromod as COO. Diarmuid’s experience and leadership will be instrumental in preparing us for US market entry, in terms of building our supply chains while ensuring our quality and regulatory processes are robust.”
Flavin will lead an increase of manufacturing capacity of Lenire—Neuromod’s medical device for the treatment of tinnitus symptoms—to meet increasing European demand and anticipated demand in the USA, pending approval from the US Food and Drug Administration (FDA), according to a company press release.
In 2021, Lenire’s availability has expanded across Europe to Ireland, Germany, the UK, Belgium, Austria and Switzerland, through Neuromod’s clinical partnerships with hearing healthcare professionals. In October 2020, Neuromod announced it had raised €10.5 million in an oversubscribed Series B financing round to fund the ongoing expansion of the availability of Lenire in Europe and the company’s FDA submission process.
Neuromod specialises in non-invasive neuromodulation technologies and has developed Lenire, the first non-invasive bimodal neuromodulation device for the treatment of tinnitus, which has shown in large-scale clinical trials to reduce the symptoms of tinnitus, the release adds. Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe.
